Suita, Japan

Tsugutaka Ito

This inventor holds 1 USPTO granted patent. Top assignee: Dainippon Pharmaceutical Company, Limited. Active years: 1985.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 1985

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tsugutaka Ito: Innovator in Muscle Relaxant Development

Introduction

Tsugutaka Ito is a notable inventor based in Suita, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of muscle relaxants. His work has implications for the treatment of spasticity in mammals, including humans.

Latest Patents

Tsugutaka Ito holds a patent for the compound 1-(2,3-Dimethyl-4-methoxyphenyl)-2-methyl-3-(1-pyrrolidinyl)-1-propanone. This compound, along with its pharmaceutically acceptable acid addition salts, is recognized for its utility as a centrally acting muscle relaxant. The patent also covers the process for the preparation of this compound and pharmaceutical compositions containing it as an active ingredient.

Career Highlights

Tsugutaka Ito is associated with Dainippon Pharmaceutical Company, Limited, where he has been instrumental in advancing pharmaceutical research and development. His innovative approach has led to the creation of effective treatments for muscle spasticity.

Collaborations

Throughout his career, Tsugutaka Ito has collaborated with esteemed colleagues, including Tatsuya Kon and Tadahiko Karasawa. These partnerships have fostered a collaborative environment that enhances the development of new therapeutic solutions.

Conclusion

In summary, Tsugutaka Ito is a prominent inventor whose work in muscle relaxants has made a significant impact in the pharmaceutical industry. His contributions continue to influence the treatment of spasticity, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…